Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors
Molecular Pharmaceutics · 03.08.2026 · 23 (8) · 4144-4154
DOI: 10.1021/acs.molpharmaceut.6c00178 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pharmaceutics, online erschienen am 16.07.2026. Verfasst von Mengqi Shi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore119074, Singapore. Hauptthemen laut MEDLINE: Lutetium, Gelatinases, Membrane Proteins, Serine Endopeptidases. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Research Foundation, National Medical Research Council, National University of Singapore.
Abstract (Originalsprache)
Fibroblast activation protein (FAP)-targeted radiotheranostics show strong promise for cancer imaging and therapy, yet their clinical translation is limited by the trade-off between rapid tumor targeting and insufficient systemic residence time. To address this challenge, we report the design and evaluation of 177Lu-Albb-2FAPI, a long-acting dimeric FAPI derivative that integrates FAPI-02 dimerization with an Evans Blue-based reversible albumin-binding motif to achieve improved tumor targeting while preserving a favorable pharmacokinetic profile. Molecular docking revealed enhanced FAP binding via avidity-driven stabilization without compromising albumin interaction. In vitro studies confirmed rapid, FAP-specific cellular uptake, while in vivo SPECT/CT imaging and biodistribution analyses demonstrated higher and more sustained tumor accumulation, together with improved early tumor-to-background contrast, compared with the monomeric analogue Albb-1FAPI. In the Panc02 tumor model, characterized by moderate FAP expression, 177Lu-Albb-2FAPI exhibited durable tumor retention and induced rapid tumor regression while preserving hematological safety. By coupling dimerization-enhanced target engagement with controlled albumin binding, 177Lu-Albb-2FAPI overcomes key diagnostic and therapeutic limitations of existing long-acting FAP radioligands, establishing a refined molecular design strategy for next-generation FAP-targeted radiotheranostics with strong translational potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore119074, Singapore.
- Center for Nuclear Medicine and Molecular Imaging (CNMMI), Shandong Cancer Hospital and Institute, Jinan250117, China.
ORCID-Profile: Jingjing Zhang, Xiaoyuan Chen
Förderung
- National Research Foundation
- National Medical Research Council
- National University of Singapore
- Ministry of Education - Singapore
Zitieren
APA
Shi, M., Wen, X., Tao, Y., Zhang, J., & Chen, X. (2026). Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors. Molecular Pharmaceutics, 23(8), 4144-4154. https://doi.org/10.1021/acs.molpharmaceut.6c00178
Vancouver
Shi M, Wen X, Tao Y, Zhang J, Chen X. Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors. Molecular Pharmaceutics. 2026;23(8):4144-4154. doi:10.1021/acs.molpharmaceut.6c00178
BibTeX
@article{Shi2026,
author = {Shi, Mengqi and Wen, Xuejun and Tao, Yucen and Zhang, Jingjing and Chen, Xiaoyuan},
title = {Development of a Long-Acting FAPI Dimer Albb-2FAPI for Diagnosis and Therapy of FAP-Positive Tumors},
journal = {Molecular Pharmaceutics},
year = {2026},
volume = {23},
number = {8},
pages = {4144--4154},
doi = {10.1021/acs.molpharmaceut.6c00178}
}
EUVIMED